Zusammenfassung
Ulcus ventriculi und duodeni sind Schleimhautdefekte, die kraterförmig über die Lamina muscularis mucosae hinaus in die Wand von Magen oder Duodenum penetrieren. Prädilektionsort des Ulcus ventriculi ist die kleine Kurvatur des Magens, des Ulcus duodeni der Bulbus duodeni. Die Inzidenz der Ulkuskrankheit ist großen geographischen Schwankungen unterworfen. Epidemiologische Studien in Nordeuropa haben gezeigt, daß pro Jahr 4 von 10000 Personen an einem Ulcus ventriculi und 13 von 10000 an einem Ulcus duodeni erkranken, wobei in den letzten 20 Jahren die Häufigkeit der Ulkuskrankheit eindeutig abnimmt [1]. Männer sind etwa doppelt so häufig betroffen wie Frauen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Sonnenberg A (1985) Geographic and temporal variations in the occurrence of peptic ulcer disease. Scand J Gastroenterol 20 [Suppl] 110: 11–24
Johansson C, Kollberg B, Nordemar R, Samuelson K, Bergström S (1980) Protective effect of prostaglandin E2 in the gastrointestinal tract during indomethacin treatment of rheumatic diseases. Gastroenterology 78:479–483
Du Plessis DJ (1965) Pathogenesis of gastric ulceration. Lancet I: 974–978
Dragstedt LL, Woddward ER (1970) Gastric stasis -a cause of gastric ulcers. Scand J Gastroenterol [Suppl.] 6: 243–252
Price AB, Levi J, Dolby JM, Dunscombe PL, Smith A, Clark J, Stephenson ML (1985) Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. Gut 26: 1183–1188
Bode G, Malfertheiner P, Ditschuneit H (1987) Invasion of Campylobacter -like organisms in the duodenal mucosa in patients with active duodenal ulcer. Klin Wochenschr 65: 144–146
Slomiany BL, Bilski J, Sarosiek J et al. (1987) Campylobacter pyloridis degrades mucin and undermines gastric mucosal integrity. Biochem Biophys Res Commun 144: 307–314
Coghlan JG, Humphries H, Dooley C et al. (1987) Campylobacter pylori and recurrence of duodenal ulcers -a 12 month follow up study. Lancet II:1109–1111
Barakat MH, Menon KN, Badawi AR (1984) Cigarette smoking and duodenal ulcer healing. An endoscopic study of 197 patients. Digestion 29: 85–90
Blum AL (1985) Stellung der Antacida in der modernen Ulkus-Therapie. Dtsch Med Wochenschr 110: 3–7
Tarnawski A, Hollander D, Cummings D, Krause UJ, Gergely R, Zipser D (1984) Are antacids acid neutralizers only? Histologic, ultrastructural and functional changes in normal gastric mucosa induced by antacids. Gastroenterology 86: 1276 (Abstract)
Becker G, Overhoff H, Forth W (1979) 1st Aluminium ungiftig? Dtsch Ärztebl 24: 1639–1642
Holtermüller KH, Büchler R, Sinterhauf K (1975) Die Wirkung von oralem Calcium und Magnesium auf die Magensäuresekretion und Gastrinfreisetzung bei Patienten mit Ulcus duodeni. Verh Dtsch Ges Inn Med 81: 1237–1238
Fordtran JS, Morawsky SG, Richardson CT (1973) In vivo and in vitro evaluation of liquid antacids. N Engl J Med 288: 923–928
Peterson WL, Fordtran JS (1978) Reduction of gastric acidity. In: Sleisenger MH, Fordtran JS (eds) Gastrointestinal disease. Saunders, Philadelphia London Toronto, pp 891–913
Domschke W, Lux G, Domschke S (1980) Furan H2-Antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than Cimetidine. Gastoenterology 79: 1267–1271
Sewing KF, Billian A, Malchow H (1980) Comparative study with ranitidine and Cimetidine on gastric secretion in normal volunteers. Gut 21: 750–752
Brater DG, Peters MN, Eskelman FN, Richardson CT (1982) Clinical comparison of Cimetidine and ranitidine. Clin Pharmacol Ther 32: 484–488
Miwa M, Tani N, Miwa T (1984) Inhibiton of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects. Int J Clin Pharmacol 4: 214–217
Peter P, Kiene K, Gouvers JJ et al. (1978) Cimetidin in der Behandlung des Ulcus duodeni. Dtsch Med Wochenschr 103: 1163–1166
Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Ranitidine, a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 24: 267–303
Dammann HG, Barbara L, Bianchi-Porro G et al. (1985) Beschleunigte Heilung des Ulcus ventriculi unter einer abendlichen Einzeldosis von Famotidin. Schweiz Med Wochenschr 115: 484–488
Farley AD, Lévesque P, Pare ABR et al. (1985) A comparative trial of ranitidine 300 mg at night with ranitidine 150 mg twice daily in the treatment of duodenal and gastric ulcer. Am J Gastroenterol 9: 665–668
Bardhan KD (1981) Medical treatment of duodenal ulcer: a review. Trop Gastroenterol 2: 4–33
Gitlin N, McCullough AJ, Smith JL, Mantell G, Berman R et al. (1987) A mulitcenter, doubleblind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology 92: 48–53
Hartmann H, Fölsch UR (1988) Famotidine versus Cimetidine in the treatment of acute duodenal ulcer. Digestion 39: 156–161
Rohner HG, Gugler R (1986) Treatment of active duodenal ulcers with famotidine. A double-blind comparison with ranitidine. Am J Med 81 [Suppl. 4B]: 13–16
Gray GR, Smith IS, McKenzie I, Gillespie G (1977) Long term Cimetidine in the management of severe duodenal ulcer dyspepsia. Gastroenterology 74:397–401
McGuigan (1981) A consideration of the adverse effects of Cimetidine. Gastroenterology 80: 181–192
Powell JR, Donn KH (1983) The pharmacokinetic basis of H2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol 5: 95–113
Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC (1980) Pirenzipine distinguishes between different subclasses of muscarinic receptors. Nature 283: 90–92
Barbara L, Belsasso E, Bianchi-Porro G et al. (1979) Pirenzipine in duodenal ulcer. A multicentre double-blind controlled clinical trial: second of two parts. Scand J Gastroenterol 14 [Suppl. 57]: 33–39
Van Deventer GM, Schneidman D, Walsh JH (1985) Sucralfate and Cimetidine as single agents and in combination for treatment of active duodenal ulcers. A double-blind, placebo-controlled trial. Am J Med 79 [Suppl. 2C]: 39–44
Blum AL, Bode JC, Manegold BC, Domschke W, Feurle G, Hammer B, Hackenberg K (1986) Therapie des Ulcus ventriculi mit Sucralfat und Ranitidin. Dtsch Med Wochenschr 111: 1910–1915
Marks IN, Wright JP, Gilinksy NH, Girwood AH, Tobias R, Boyd E, Kalvaria I (1986) A comparison of sucralfate dosage schedule in duodenal ulcer healing. J Clin Gastroenterol 8: 419–423
Pai S, Melethil S, Cuddy P, Hall T (1987) Elevation of serum aluminium in humans on a two-day sucralfate regimen. J Clin Pharmacol 27: 213–215
Peskar BM, Hoppe U, Lange K, Peskar BA (1988) Effects of non-steroi-dal anti-inflammatory drugs on rat gastric mucosal leukotriene C4 and prostanoid release: relation to ethanol-induced injury. Br J Pharmacol 93:937–943
Tytgat GNJ (1987) Colloidal bismuth subcitrate in peptic ulcer -a review. Digestion 37 [Suppl. 2]: 31–41
Lane MR, Lee SP (1988) Recurrence of duodenal ulcer after medical treatment. Lancet I: 1147–1149
Robert A (1979) Cytoprotection by prostaglandins. Gastroenterology 77: 761–767
Hawkey CJ, Walt RP (1986) Prostaglandins for peptic ulcer: a promise unfulfilled. Lancet II: 1084–1086
Clissold SP, Campoli-Richards DM (1986) Omeprazol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syn drome. Drugs 32: 15–47
Naesdal J, Lind T, Bergsäker-Aspöy J, Bernklev T, Farup PG, Gillberg R, Halvorsen L (1985) The rate of healing of duodenal ulcers during omeprazole treatment. Scand J Gastroenterol 20: 691–695
Walan A, Bader JP, Classen M, Lamers C, Piper DW, Rutgersson K, Eriksson S (1989) Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320: 69–75
Classen M, Dammann HG, Domschke W, Hengels KJ, Hüthemann W, Londong W, Rehner M (1985) Kurzzeittherapie des Ulcus duodeni mit Omeprazol und Ranitidin. Dtsch Med Wochenschr 110: 210–215
Tytgat GNJ, Lamers CBHW, Hameeteman W, Jansen JMBJ, Wilson JA (1987) Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther 1: 31–36
Haven N (1986) Enterochromaffin like cell carcinoids of gastric mucosa in rats after life long inhibiton of gastric secretion. Digestion 35 [Suppl. 1]: 42–55
Lanzon-Miller S, Pounder RE, Hamilton MR et al. (1987) Twentyfour-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1: 239–251
Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G (1988) Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39: 126–135
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fölsch, U.R., Junge, U. (1990). Ulkuskrankheit. In: Medikamentöse Therapie in der Gastroenterologie. Kliniktaschenbücher. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-87466-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-87466-6_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-51886-0
Online ISBN: 978-3-642-87466-6
eBook Packages: Springer Book Archive